Deborah Knobelman - Jun 8, 2022 Form 3 Insider Report for Senti Biosciences, Inc.\ (SNTI)

Role
Chief Financial Officer
Signature
/s/ Mike Rhee, attorney-in-fact
Stock symbol
SNTI
Transactions as of
Jun 8, 2022
Transactions value $
$0
Form type
3
Date filed
6/15/2022, 06:00 PM
Next filing
Oct 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SNTI Stock Option (Right to Buy) Jun 8, 2022 Common Stock 147K $7.87 Direct F1
holding SNTI Stock Option (Right to Buy) Jun 8, 2022 Common Stock 948K $9.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vested on May 20, 2022 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.
F2 25% of the shares underlying this option vest on June 8, 2023 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney Effective immediately following the Effective Time as defined in that certain Business Combination Agreement dated as of December 19, 2021, as amended, by and among Senti Sub I, Inc. (f/k/a Senti Biosciences, Inc.), Issuer (f/k/a Dynamics Special Purpose Corp.), and Explore Merger Sub, Inc., the reporting person was elected as an executive officer of the Issuer.